nach oben

Drugs & Aging

Erschienen in:

21.06.2023 | Current Opinion

Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence

verfasst von: Paru S. David, Talia Sobel, Sabrina Sahni, Jaya Mehta, Juliana M. Kling

Erschienen in: Drugs & Aging | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Menopause occurs in all women. During the menopause transition, 80% of women experience vasomotor symptoms that can last an average of 7–10 years or longer, sometimes into the seventh and eighth decades of life. Understanding how to manage vasomotor symptoms (VMS) in older menopausal women is important since these symptoms can negatively impact quality of life. This review provides a practical guide on how to approach VMS treatment either with menopausal hormone therapy or non-hormone options. When initiating, as well as continuing hormone therapy, the factors clinicians should consider as they weigh risks and benefits include assessing a woman’s risks related to cardiovascular disease, breast cancer, and osteoporosis. Utilizing a shared decision-making approach in regard to menopausal symptom management should aim to support women and help them maintain health and quality of life.

Faubion SS, et al. The 2022 hormone therapy position statement of The North American Menopause Society’. Menopause. 2022;29(7):2022. https://doi.org/10.1097/GME.0000000000002028.CrossRef

Greendale GA, Karlamangla AS, Maki PM. The menopause transition and cognition. JAMA J Am Med Assoc. 2020. https://doi.org/10.1001/jama.2020.1757.CrossRef

Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000. https://doi.org/10.1097/00006250-200009000-00007.CrossRefPubMed

Maki PM, Thurston RC. Menopause and brain health: hormonal changes are only part of the story. Front Neurol. 2020. https://doi.org/10.3389/fneur.2020.562275.CrossRefPubMedPubMedCentral

Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: A systematic review. Climacteric. 2007. https://doi.org/10.1080/13697130601181486.CrossRefPubMed

Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, DiBonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013. https://doi.org/10.1097/gme.0b013e31827d38a5.CrossRefPubMed

Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. Study of Women’s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–9.CrossRefPubMedPubMedCentral

David PS, et al. Vasomotor symptoms in women over 60: results from the data registry on experiences of aging, menopause, and sexuality (DREAMS). Menopause. 2018. https://doi.org/10.1097/GME.0000000000001126.CrossRefPubMed

Barnabei VM, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002. https://doi.org/10.1016/S0029-7844(02)02369-4.CrossRefPubMed

10.

Bromberger JT, et al. ‘Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation Menopause. 2013. https://doi.org/10.1097/gme.0b013e3182730599.CrossRefPubMed

11.

Bromberger JT, et al. Depressive symptoms during the menopausal transition: The Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2007. https://doi.org/10.1016/j.jad.2007.01.034.CrossRefPubMedPubMedCentral

12.

Kravitz HM, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008. https://doi.org/10.5665/sleep/31.7.979.CrossRefPubMedPubMedCentral

13.

Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease. Circulation. 2008. https://doi.org/10.1161/circulationaha.108.776823.CrossRefPubMedPubMedCentral

14.

Crandall CJ, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab. 2015. https://doi.org/10.1210/jc.2014-3062.CrossRefPubMedPubMedCentral

15.

Maki PM. Verbal memory and menopause. Maturitas. 2015. https://doi.org/10.1016/j.maturitas.2015.07.023.CrossRefPubMed

16.

Sarrel P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015. https://doi.org/10.1097/GME.0000000000000320.CrossRefPubMed

17.

Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause. 2015. https://doi.org/10.1097/GME.0000000000000383.CrossRefPubMed

18.

Manson JE et al. The Women’s Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases. JAMA. 2013;310(13):1353–68.

19.

Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021. https://doi.org/10.1210/clinem/dgaa764.CrossRefPubMedPubMedCentral

20.

Maki PM, et al. Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations. Menopause. 2018. https://doi.org/10.1097/GME.0000000000001174.CrossRefPubMed

21.

Mintziori G, et al. EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas. 2015. https://doi.org/10.1016/j.maturitas.2015.04.009.CrossRefPubMed

22.

Cansino C. ACOG COMMITTEE OPINION number 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018. https://doi.org/10.1097/AOG.0000000000002631.CrossRef

23.

Roberts H, Hickey M, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: A Cochrane review summary. Maturitas. 2014. https://doi.org/10.1016/j.maturitas.2013.10.002.CrossRefPubMed

24.

Thurston RC, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in swan. J Am Heart Assoc. 2021. https://doi.org/10.1161/JAHA.120.017416.CrossRefPubMedPubMedCentral

25.

Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004. https://doi.org/10.1111/j.1525-1497.2004.30281.x.CrossRefPubMedPubMedCentral

26.

Salpeter SR, Walsh JME, Greyber E, Salpeter EE. ‘Brief Report: Coronary heart disease events associated with hormone therapy in younger and older women—A meta-analysis. J Gen Intern Medicine. 2006. https://doi.org/10.1111/j.1525-1497.2006.00389.x. (Journal of General Internal Medicine, vol. 23, no. 10. 2008. doi: 10.1007/s11606-008-0762-2).CrossRef

27.

Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J. 2022. https://doi.org/10.1097/PPO.0000000000000591.CrossRefPubMedPubMedCentral

28.

Stuenkel CA. Managing menopausal vasomotor symptoms in older women. Maturitas. 2021. https://doi.org/10.1016/j.maturitas.2020.08.005.CrossRefPubMed

29.

Manson JAE, Bassuk SS, Kaunitz AM, Pinkerton JAV. The Women’s Health Initiative trials of menopausal hormone therapy: lessons learned. Menopause. 2020. https://doi.org/10.1097/GME.0000000000001553.CrossRefPubMedPubMedCentral

30.

Shufelt, CL, et al. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–90. https://doi.org/10.1097/GME.0000000000002200.CrossRef

31.

Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Women’s Health. 2015. https://doi.org/10.2147/IJWH.S50804.CrossRef

32.

Riemma G, et al. Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials. Medicina (Lithuania). 2019. https://doi.org/10.3390/medicina55090554.CrossRef

33.

Schroeck JL, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Therape. 2016. https://doi.org/10.1016/j.clinthera.2016.09.010.CrossRef

34.

Simon JA, et al. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause. 2016. https://doi.org/10.1097/GME.0000000000000773.CrossRefPubMed

35.

Leon-Ferre RA, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: A randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectrum. 2020. https://doi.org/10.1093/jncics/pkz088.CrossRefPubMed

36.

Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021. https://doi.org/10.1007/s00192-021-04909-5.CrossRefPubMed

37.

Santoro N, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: Results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020. https://doi.org/10.1097/GME.0000000000001621.CrossRefPubMedPubMedCentral

38.

Johnson KA, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023. https://doi.org/10.1210/clinem/dgad058.CrossRefPubMedPubMedCentral

39.

Fraser GL, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020. https://doi.org/10.1097/GME.0000000000001510.CrossRefPubMedPubMedCentral

40.

Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020. https://doi.org/10.1097/GME.0000000000001500.CrossRefPubMedPubMedCentral

41.

‘FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause. Accessed 25 May 2023.

42.

Goldsborough E, Osuji N, Blaha MJ. Assessment of cardiovascular disease risk: a 2022 update. Endocrinol Metab Clin N Am. 2022. https://doi.org/10.1016/j.ecl.2022.02.005.CrossRef

43.

Triantafyllou A, Douma S. ‘Cardiovascular risk assessment in elderly individuals without overt CVD disease. Could traditional risk factors fit in all ages? J Clin Hypertens. 2019. https://doi.org/10.1111/jch.13616.CrossRef

44.

Rich-Edwards JW, Fraser A, Lawlor DA, Catov JM. Pregnancy characteristics and women’s future cardiovascular health: An underused opportunity to improve women’s health? Epidemiol Rev. 2014. https://doi.org/10.1093/epirev/mxt006.CrossRefPubMed

45.

Maas AHEM. Hormone therapy and cardiovascular disease: Benefits and harms. Best Pract Res Clin Endocrinol Metab. 2021. https://doi.org/10.1016/j.beem.2021.101576.CrossRefPubMed

46.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 diabetes—Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020. https://doi.org/10.2991/JEGH.K.191028.001.CrossRefPubMedPubMedCentral

47.

Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006. https://doi.org/10.1111/j.1463-1326.2005.00545.x.CrossRefPubMed

48.

Xu Y, Lin J, Wang S, Xiong J, Zhu Q. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. Kaohsiung J Med Sci. 2014. https://doi.org/10.1016/j.kjms.2014.03.002.CrossRefPubMed

49.

Brentnall AR, Cuzick J, Buist DSM, Bowles EJA. Long-Term accuracy of breast cancer risk assessment combining classic risk factors and breast density. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.0174.CrossRefPubMedPubMedCentral

50.

Bodewes FTH, van Asselt AA, Dorrius MD, Greuter MJW, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022. https://doi.org/10.1016/j.breast.2022.09.007.CrossRefPubMedPubMedCentral

51.

Islami F, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21440.CrossRefPubMed

52.

LeBoff MS, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022. https://doi.org/10.1007/s00198-021-05900-y.CrossRefPubMedPubMedCentral

53.

Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab. 2021. https://doi.org/10.1016/j.beem.2021.101578.CrossRefPubMedPubMedCentral

54.

Shufelt CL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the Women’s Health Initiative Observational Study. Menopause. 2014. https://doi.org/10.1097/GME.0b013e31829a64f9.CrossRefPubMedPubMedCentral

55.

Hsia J, et al. Conjugated equine estrogens and coronary heart disease: The women’s health initiative. Arch Intern Med. 2006. https://doi.org/10.1001/archinte.166.3.357.CrossRefPubMed

56.

Manson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003. https://doi.org/10.1056/nejmoa030808.CrossRefPubMed

57.

Stampfer MJ, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses’ health study. Obstet Gynecol Surv. 1992. https://doi.org/10.1097/00006254-199202000-00027.CrossRef

58.

Shufelt CL, Manson JAE. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery. J Clin Endocrinol Metab. 2021. https://doi.org/10.1210/clinem/dgab042.CrossRefPubMedPubMedCentral

59.

Mebane Sims IL. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI)Trial. JAMA J Am Med Assoc. 1995;19:95. https://doi.org/10.1001/jama.273.3.199.CrossRef

60.

Felmeden DC, Lip GYH. Hormone replacement therapy and hypertension. Blood Press. 2000. https://doi.org/10.1080/080370500448614.CrossRefPubMed

61.

Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA J Am Med Assoc. 2020. https://doi.org/10.1001/jama.2020.9482.CrossRef

62.

Abenhaim HA, Suissa S, Azoulay L, Spence AR, Czuzoj-Shulman N, Tulandi T. Menopausal hormone therapy formulation and breast cancer risk. Obstet Gynecol. 2022. https://doi.org/10.1097/AOG.0000000000004723.CrossRefPubMed

63.

Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018. https://doi.org/10.1080/13697137.2017.1421925.CrossRefPubMed

64.

Suffoletto JA, Hess R. Tapering versus cold turkey: Symptoms versus successful discontinuation of menopausal hormone therapy. Menopause. 2009. https://doi.org/10.1097/gme.0b013e3181a057db.CrossRefPubMedPubMedCentral

65.

Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy. Menopause. 2009. https://doi.org/10.1097/gme.0b013e31818fbff5.CrossRefPubMed

Titel: Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence
verfasst von: Paru S. David
Talia Sobel
Sabrina Sahni
Jaya Mehta
Juliana M. Kling
Publikationsdatum: 21.06.2023
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 8/2023
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-023-01043-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Age is No Barrier: CAR-T Therapy in Older Adults

Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review

Association of Potentially Inappropriate Medication Classes with Mortality Risk Among Older Adults Initiating Hemodialysis

Independent Association Between Use of Proton Pump Inhibitors and Muscle Wasting in Patients with Heart Failure: A Single-Center, Ambispective, Observational Study

Fall-Risk-Increasing Drugs and Gait Performance in Community-Dwelling Older Adults: Exploratory Results from the Gait and Brain Study

Guideline-Directed Medical Therapies for Heart Failure with a Reduced Ejection Fraction in Older Adults: A Narrative Review on Efficacy, Safety and Timeliness

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin